CytomX Therapeutics Inc CTMX:NASDAQ

Last Price$4.29NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/21/22

Today's Change+0.13(3.12%)
Bid (Size)$4.09 (19)
Ask (Size)$4.47 (3)
Day Low / High$4.10 - 4.38
Volume952.3 K

View Biotechnology IndustryPeer Comparison as of 01/21/2022


CytomX Therapeutics Inc ( NASDAQ )

Price: $4.29
Change: +0.13 (3.12%)
Volume: 952.3 K
4:00PM ET 1/21/2022

Precision BioSciences Inc ( NASDAQ )

Price: $4.59
Change: -0.38 (7.65%)
Volume: 1.0 M
4:00PM ET 1/21/2022

Selecta Biosciences Inc ( NASDAQ )

Price: $2.39
Change: -0.11 (4.40%)
Volume: 1.2 M
4:00PM ET 1/21/2022

Curis Inc ( NASDAQ )

Price: $3.07
Change: -0.08 (2.54%)
Volume: 2.2 M
4:00PM ET 1/21/2022

ADMA Biologics Inc ( NASDAQ )

Price: $1.45
Change: +0.02 (1.40%)
Volume: 1.9 M
4:00PM ET 1/21/2022

Read more news Recent News

FDA Clears CytomX's Investigational New Drug Application for CX-904 in Advanced Solid Tumors
9:02AM ET 1/19/2022 MT Newswires

CytomX Therapeutics (CTMX) said Wednesday the US Food and Drug Administration has cleared the investigational new drug application for CX-904 being...

Barclays Upgrades CytomX Therapeutics to Overweight from Underweight, Keeps $7 Price Target
9:41AM ET 1/18/2022 MT Newswires

CytomX Therapeutics (CTMX) has an average rating of buy and price targets ranging from $7 to $16, according to analysts polled by Capital IQ. (MT Newswires...

HC Wainwright Adjusts CytomX Therapeutics' Price Target to $11 From $12, Keeps Buy Rating
7:03AM ET 12/22/2021 MT Newswires

CytomX Therapeutics (CTMX) has an average rating of outperform and price targets ranging from $7 to $16, according to analysts polled by Capital IQ. (MT...

--JPMorgan Adjusts Price Target for CytomX Therapeutics to $10 from $12, Maintains Overweight Rating
12:43PM ET 12/21/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

View all Commentary and Analysis

The State Of Biotech In 2022
4:04AM ET 1/03/2022 Seeking Alpha

CytomX: Pullbacks Are Opportunities
5:17PM ET 12/14/2021 Seeking Alpha

CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q3 2021 Results - Earnings Call Transcript
8:37AM ET 11/07/2021 Seeking Alpha

CytomX Therapeutics, Inc. 2021 Q3 - Results - Earnings Call Presentation
4:40AM ET 11/07/2021 Seeking Alpha

Company Profile

Business DescriptionCytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA. View company web site for more details
Address151 Oyster Point Boulevard
South San Francisco, California 94080-1913
Number of Employees137
Recent SEC Filing01/10/20228-K
Chairman, President & Chief Executive OfficerSean A. McCarthy
Chief Financial Officer & Senior Vice PresidentCarlos E. Campoy
Senior Vice President & Head-ResearchMarcia P. Belvin
Chief Medical Officer & Senior Vice PresidentAlison L. Hannah

Company Highlights

Price Open$4.12
Previous Close$4.16
52 Week Range$3.67 - 10.05
Market Capitalization$279.9 M
Shares Outstanding65.2 M
SectorHealth Technology
Next Earnings Announcement02/23/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.21
Beta vs. S&P 500N/A
Revenue$59.5 M
Net Profit Margin-108.85%
Return on Equity-65.76%

Analyst Ratings as of 01/14/2022

Consensus RecommendationConsensus Icon
Powered by Factset